title: Ibuprofen in the management of neonatal Patent Ductus Arteriosus.
abstract: Patent Ductus Arteriosus (PDA) has a prevalence of approximately 25% in neonates of less than 33 weeks gestation. Failure to treat increases the mortality risk in these preterm infants. Intravenous Ibuprofen has recently been licensed in the United Kingdom as a treatment for this condition. This article reviews the clinical efficacy, side effect profile and dosing/administration schedule of this drug and discusses the warnings and precautions currently attributed to this formulation. Ibuprofen provides a further option for neonatologists in the management of PDA.
authors.affiliation: Women and Children's Services, University College London Hospitals NHS Foundation Trust, UK. simon.keady@uclh.nhs.uk
authors.forename: Simon
authors.initials: S
authors.lastname: Keady
authors.forename: Anthony
authors.initials: A
authors.lastname: Grosso
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy*; D006801:Humans; D007052:Ibuprofen / Q000009:adverse effects / Q000627:therapeutic use*; D007231:Infant, Newborn; D007262:Infusions, Intravenous
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007052:Ibuprofen